Citadel Advisors
ELTX icon

Citadel Advisors’s Elicio Therapeutics ELTX Stock Holding History

Citadel Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,978
Closed -$160K – 13962
2026
Q1 		$171K Buy
+15,978
New +$154K ﹤0.01% 11569
2024
Q4 		– Sell
-12,856
Closed -$64.7K – 14710
2024
Q3 		$64.7K Buy
+12,856
New +$57K ﹤0.01% 11635
2024
Q1 		– Sell
-14,005
Closed -$117K – 14746
2023
Q4 		$117K Sell
14,005
-2,201
-14% -$14.3K ﹤0.01% 10738
2023
Q3 		$137K Buy
+16,206
New +$154K ﹤0.01% 10496
2022
Q4 		– Sell
-1,468
Closed -$14K – 14981
2022
Q3 		$14K Sell
1,468
-4,548
-76% -$47.5K ﹤0.01% 12175
2022
Q2 		$69K Buy
+6,016
New +$96.1K ﹤0.01% 11713
2021
Q3 		– Sell
-2,386
Closed -$311K – 13971
2021
Q2 		$311K Sell
2,386
-1,110
-32% -$160K ﹤0.01% 11171
2021
Q1 		$631K Buy
+3,496
New +$675K ﹤0.01% 9171

Other funds holding ELTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's ELTX Position: Q2 2026 in Review

Citadel Advisors sold out of Elicio Therapeutics (ELTX) in Q2 2026, closing a stake of 15,978 shares — an estimated $160K sold.

Citadel Advisors first reported a position in ELTX in Q1 2021 and held it in 8 quarters. The position peaked at $631K in Q1 2021. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Citadel Advisors reported no remaining Elicio Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 15,978 Elicio Therapeutics shares in Q2 2026, an estimated $160K.
  • Citadel Advisors first reported a position in Elicio Therapeutics in Q1 2021 and held it in 8 quarters.
  • Citadel Advisors's Elicio Therapeutics position peaked at $631K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.